For the Inventor, By the Inventor

Enter assignee name

New Haven, CT, United States of America

Arvinas Operations, Inc.

USPTO Granted Patents = 57

EPO Patents = 6

Trademarks = 6

Forward Citations = 130

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Andrew Philip Crew (40 out of 72 patents)

Jing Wang (39 out of 53 patents)

Hanqing Dong (38 out of 52 patents)

4. Yimin Qian (26 out of 71 patents)

5. Michael Berlin (18 out of 40 patents)

6. Lawrence B Snyder (17 out of 47 patents)

7. Keith R Hornberger (16 out of 18 patents)

8. Craig M Crews (13 out of 33 patents)

9. Kurt Zimmermann (9 out of 26 patents)

10. Xin Chen (6 out of 17 patents)

11. Steven M Sparks (5 out of 5 patents)

12. Wei Zhang (5 out of 5 patents)

13. Saul Jaime-Figueroa (4 out of 11 patents)

14. Erika Araujo (4 out of 4 patents)

15. Meizhong Jin (4 out of 25 patents)

Core Competencies:

Targeted Protein Degradation

Cereblon Ligands

Androgen Receptor Degraders

Estrogen Receptor Modulators

Bromodomain-Containing Proteins

Rapidly Accelerated Fibrosarcoma

Tau-Protein Targeting

Mutant LRRK2 Proteolysis

Indazole Derivatives

EGFR Proteolysis

Tank-Binding Kinase-1 PROTACs

Proteolysis Modulators

57 patents: Sort by Forward Citations

1. 12473294 - Selective modulators of mutant LRRK2 proteolysis and associated methods of use (2025-11-18),

2. 12448399 - Cereblon-based KRAS degrading PROTACs and uses related thereto (2025-10-21),

3. 12441708 - Cereblon ligands and bifunctional compounds comprising the same (2025-10-14),

4. 12427144 - Compounds and methods for the targeted degradation of androgen receptor (2025-09-30),

5. 12419960 - Compounds and methods for the targeted degradation of androgen receptor and associated methods of use (2025-09-23),

6. 12312316 - Compounds and methods for the targeted degradation of androgen receptor (2025-05-27),

7. 12310975 - Modulators of BCL6 proteolysis and associated methods of use (2025-05-27),

8. 12286419 - Methods of manufacturing a bifunctional compound (2025-04-29),

9. 12275716 - Modulators of estrogen receptor proteolysis and associated methods of use (2025-04-14),

10. 12264157 - Compounds and methods for the enhanced degradation of targeted proteins (2025-04-01),

11. 12239711 - Cereblon ligands and bifunctional compounds comprising the same (2025-03-04),

12. 12208095 - Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders (2025-01-28),

13. 12180193 - Accelerating fibrosarcoma protein degrading compounds and associated methods of use (2024-12-31),

14. 12172981 - Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders (2024-12-24),

15. 12171831 - Compounds and methods for the targeted degradation of bromodomain- containing proteins (2024-12-24),

Arvinas Operations, Inc. is a pharmaceutical company focused on developing innovative targeted protein degradation therapies to treat cancer and other diseases. With a proprietary PROTAC® platform, Arvinas aims to address previously undruggable targets and revolutionize drug discovery and development. The company leverages its deep expertise in protein degradation and medicinal chemistry to discover and design small molecule drugs that selectively target disease-causing proteins for degradation, leading to potential therapies with enhanced efficacy and reduced side effects.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

57 Patents

#7 in New Haven, CT

#144 in Connecticut

#6,042 in US

#12,168 in the World

New Haven, CT, United States of America

Arvinas Operations, Inc.

Forward Citations = 130

36 inventors:

Andrew Philip Crew (40 out of 72 patents)

Jing Wang (39 out of 53 patents)

Hanqing Dong (38 out of 52 patents)

4. Yimin Qian (26 out of 71 patents)

5. Michael Berlin (18 out of 40 patents)

Please report any incorrect information to support@idiyas.com

Loading…